Ovid Therapeutics (OVID) Net Margin (2020 - 2026)

Ovid Therapeutics (OVID) has reported Net Margin for 7 consecutive years, with 2047.61% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Margin fell 197293.0% year-over-year to 2047.61%; the trailing twelve-month figure through Jun 2026 stood at 2178.9% (down 160488.0% YoY), and the FY2025 full-year result was 240.13%, up 443001.0% from the prior year.
• Net Margin slipped to 2047.61% in Q2 2026 per OVID's latest filing, from 1345.82% in the prior quarter.
• Across five years, Net Margin topped out at 5042.01% in Q2 2024 and bottomed at 107798.33% in Q3 2022.
• Historically, Net Margin has averaged 14541.04% across 5 years, with a median of 8653.28% in 2024.
• The widest YoY moves for Net Margin: up 9747448 bps in 2023, down 1912190 bps in 2023.
• Over 5 years, Net Margin stood at 24859.09% in 2022, then soared by 57 bps to 10790.14% in 2023, then slipped by 13 bps to 12175.0% in 2024, then soared by 111 bps to 1345.82% in 2025, then sank by 252 bps to 2047.61% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 2047.61%, 1345.82%, and 9210.61% for Q2 2026, Q4 2025, and Q3 2025 respectively.